eteraflex connects

What eteraflex connects does

eteraflex connects is a US-headquartered Clinical Research Organization (CRO), founded circa 2007 and currently operating from Princeton, NJ, that delivers clinical trial execution, regulatory affairs, and Functional Service Provider (FSP) programs in India for small and mid-cap biotechnology companies and medical device manufacturers. The company positions itself as a bridge between US-grade regulatory governance and India's clinical scale, claiming 4-5 week CDSCO approval timelines versus a 12-16 week industry average, a 98% first-submission approval rate across 150+ clearances, and zero critical audit findings over 24 months. Operational footprint comprises a headquarters in Princeton, a regional office in Canton, MA, and four India delivery centers in Hyderabad, Chennai, Delhi, and Bengaluru.

The delivery model rests on two proprietary technology platforms: ClintrialX, an AI-enhanced clinical trial data management platform claiming four-week database lock and 65% reduction in manual review cycles through machine learning and predictive issue tracking, and HeliX, an FSP program management platform providing predictive resource allocation, automated vendor and compliance monitoring, and real-time performance metrics. Both platforms are described as FDA/EMA/CDSCO-compliant and are coupled with six service lines — End-to-End Clinical Trials (Phase I-IV), Regulatory Excellence, FSP Programs, Regulatory Strategy, Medical Device Trials, and India Licensing Partnership Advisory — spanning oncology, immunology, rare diseases, cardiovascular, neurology, pediatrics, and medical device classes I-III including SaMD, IVD, gene/cell therapy, and biosimilars.

Revenue is generated primarily through project-based professional services contracts with biotechnology sponsors and medical device manufacturers seeking to run trials in India, supplemented by multi-year FSP engagements. Pricing is quote-based under flexible engagement models with claimed 4-6X ROI guarantees within 12 months and 45-65% cost reduction versus US/EU benchmarks; multi-year contract structures are used for FSP programs. The go-to-market is consultative enterprise field sales led from the US, with direct engagement through strategy calls, supported by content marketing and a LinkedIn presence. Revenue is not publicly disclosed and no funding rounds, M&A, or institutional investor relationships are recorded.

Name

eteraflex connects

Legal name

eteraflex connects

Website

https://eteraflexconnects.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

US-headquartered Clinical Research Organization delivering clinical trial execution, regulatory affairs, and Functional Service Provider programs in India for small and mid-cap biotech and medical device manufacturers via proprietary platforms ClintrialX and HeliX.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)

akta.pro secondary industries

Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

Keywords

• Clinical trial services
• Contract research organization
• Regulatory affairs consulting
• Functional service provider
• Medical device trials

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO services including clinical trials (Phase I-IV), regulatory affairs, FSP programs, medical device trials, and India licensing partnership advisory. Revenue generated through project-based professional service contracts with biotechnology companies and medical device manufacturers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

eteraflex connects is a US-based clinical research organization that delivers end-to-end CRO services for small and mid-cap biotechnology companies and medical device manufacturers executing trials in India. Core offerings include Phase I-IV clinical trials, CDSCO regulatory affairs and strategy, Functional Service Provider (FSP) programs, medical device clinical evaluations (Class I-III), and India licensing partnership advisory. Services are enabled by two proprietary platforms—ClintrialX (AI-powered data management with 4-week database lock) and HeliX (FSP operations and predictive analytics)—delivered through a US-India dual delivery model covering 240+ validated research sites and 180+ investigators.

Product overview

eteraflex connects operates as a US-based Clinical Research Organization (CRO) delivering comprehensive clinical research services through a dual-platform architecture. The company offers two proprietary technology platforms: ClintrialX (AI-powered data management with 4-week database lock capability) and HeliX (FSP operations and optimization platform), complemented by six core service offerings including Clinical Trials (Phase I-IV), Regulatory Excellence, FSP Programs, Regulatory Strategy, Medical Device Trials, and India Licensing Partnership Advisory. The integrated model combines US governance and strategy with India operational execution across 240+ validated clinical research sites.

Differentiator

Problem solved

Functional benefit

Brands

• ClintrialX: Proprietary AI-powered data management and enrollment tracking platform for clinical trials
• HeliX

Products and services

• Clinical Trials Services End-to-end clinical research services across Phase I-IV programs for biotechnology companies and medical device manufacturers, including protocol design, site management, patient recruitment, data management, and regulatory submission support across 240+ validated research sites.
• Regulatory Excellence Services CDSCO consulting, drug approvals, and clinical trial regulatory submissions service delivering 4-5 week clearance timelines, a 98% first-submission success rate, and 150+ approvals across drugs, biologics, medical devices, and clinical trials.
• FSP Programs Functional Service Provider programs offering Dedicated Team FSP, Hybrid FSP, and Technology-Accelerated Delivery models with real-time operational intelligence, automated QA workflows, predictive analytics, and executive dashboards across 450+ professionals.
• Regulatory Strategy Services End-to-end regulatory affairs services spanning preclinical pathway design to market authorization and post-market compliance, including dossier preparation, CDSCO coordination, lifecycle compliance, and regulatory intelligence platform integration.
• Medical Device Trials Services Medical device clinical evaluations from feasibility to pivotal studies for Class I-III devices, supporting implantable technologies, diagnostic systems, digital health (SaMD), IVD diagnostics, gene/cell therapy, biosimilars, and rare disease treatments with accelerated 6-8 week manufacturing licenses.
• India Licensing Partnership Advisory Comprehensive end-to-end India licensing support integrating regulatory strategy, clinical execution, and market access for global sponsors licensing FDA-approved assets into India, including regulatory strategy and waiver engineering, bridge study design, partner identification, and market access and lifecycle management.

Quantifiable outcome

• Reduces trial startup timeline by 6-9 months
• +10 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Veeva Systems: Veeva is a cloud software provider for life sciences, including clinical trial management (Veeva Vault EDC, CTMS) that increasingly overlaps with in-house CRO technology. Comparable to eteraflex because its trial platforms (e.g., EDC, CTMS) directly compete with or could integrate with ClintrialX/HeliX, and Veeva's life sciences focus puts it adjacent to eteraflex's biotech sponsor set.

Direct peers

• Medpace: Medpace is a mid-to-large full-service CRO with strong biotech and medical device focus and operational models emphasizing quality and therapeutic specialization. Comparable to eteraflex because both target the small/mid-cap biotech and device sponsor segment and emphasize rigorous execution metrics similar to eteraflex's inspection pass-rate positioning.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO focused on complex trials in therapeutic areas such as neuroscience, cardiometabolic, and rare diseases. Comparable to eteraflex because both target small/mid-cap biotech and operate mid-scale full-service clinical operations with technology-enabled delivery models.
• Clinipace Worldwide: Clinipace is a mid-size full-service CRO serving small/mid-cap biotech and device sponsors across therapeutic areas. Comparable to eteraflex because both are mid-tier CROs targeting the same sponsor segment with technology-augmented full-service and FSP engagements.

Broad incumbents

• IQVIA: IQVIA is the largest global CRO and a broad incumbent offering end-to-end clinical operations, real-world evidence, and technology-enabled trial management across all geographies, including India. Comparable because it competes for the same biotech and device sponsor RFPs eteraflex targets, though IQVIA's portfolio and scale dwarf eteraflex's.
• ICON plc: ICON is a top-tier global CRO with broad Phase I-IV services and a meaningful Asia-Pacific footprint, including India delivery centers. Comparable to eteraflex because it serves the same biotech and medical device sponsor base with full-service clinical operations and FSP offerings, though at significantly larger scale.
• Parexel International: Parexel is a global CRO with deep biotech and medical device expertise and significant Asia-Pacific delivery capability. Comparable to eteraflex because it competes head-to-head for global clinical trial and regulatory strategy mandates from small and mid-cap sponsors seeking India execution.
• Syneos Health: Syneos Health is a biopharmaceutical solutions organization offering clinical development and commercial services globally with established Asia-Pacific operations. Comparable to eteraflex because it competes for the same biotech and device clinical trial engagements and offers FSP-style resourcing and consulting.
• Charles River Laboratories: Charles River is a global CRO/CDMO with research models, discovery, and safety assessment plus clinical trial support, including a sizable India presence. Comparable to eteraflex because it addresses similar biotech device clients and offers comparable FSP-style engagements alongside broader preclinical capabilities.

Regional players

• Novotech: Novotech is an Asia-Pacific-focused CRO with deep Australia/Asia trial operations, particularly attractive for biotech sponsors seeking Asia-centric trial execution. Comparable to eteraflex because both specialize in regional trial execution for global biotech and compete for sponsors wanting non-US/EU trial geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eteraflex-connects

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eteraflex connects